Page 2092 - Williams Hematology ( PDFDrive )

2066 Part XII: Hemostasis and Thrombosis Chapter 120: Hereditary Qualitative Platelet Disorders 2067

257. Waldenstrom E, Holmberg L, Axelsson U, et al: Bernard-Soulier syndrome in two 288. Matsubara Y, Murata M, Sugita K, Ikeda Y: Identification of a novel point mutation
Swedish families: Effect of DDAVP on bleeding time. Eur J Haematol 46:182–187, in platelet glycoprotein Ibalpha, Gly to Ser at residue 233, in a Japanese family with
1991. platelet- type von Willebrand disease. J Thromb Haemost 1:2198–2205, 2003.
258. Evensen SA, Solum NO, Grottum KA, Hovig T: Familial bleeding disorder with a mod- 289. Kanaji S, Fahs SA, Ware J, et al: Non-myeloablative conditioning with busulfan before
erate thrombocytopenia and giant blood platelets. Scand J Haematol 13:203–214, 1974. hematopoietic stem cell transplantation leads to phenotypic correction of murine
259. Greco NJ, Tandon NN, Jones GD, et al: Contributions of glycoprotein Ib and the seven Bernard-Soulier syndrome. J Thromb Haemost 12:1726–1732, 2014.
transmembrane domain receptor to increases in platelet cytoplasmic [Ca 2+] induced 290. Uff S, Clemetson JM, Harrison T, et al: Crystal structure of the platelet glycoprotein
by α-thrombin. Biochemistry 35:906–914, 1996. Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation.
260. Celikel R, McClintock RA, Roberts JR, et al: Modulation of alpha-thrombin function by J Biol Chem 277:35657–35663, 2002.
distinct interactions with platelet glycoprotein Ibalpha. Science 301:218–221, 2003. 291. Huizinga EG, Tsuji S, Romijn RA, et al: Structures of glycoprotein Ibalpha and its com-
261. Dumas JJ, Kumar R, Seehra J, et al: Crystal structure of the GpIbalpha-thrombin com- plex with von Willebrand factor A1 domain. Science 297:1176–1179, 2002.
plex essential for platelet aggregation. Science 301:222–226, 2003. 292. Enayat S, Ravanbod S, Rassoulzadegan M, et al: A novel D235Y mutation in the GP1BA
262. McGowan EB, Ding A, Detwiler TC: Correlation of thrombin-induced glycoprotein V gene enhances platelet interaction with von Willebrand factor in an Iranian family with
hydrolysis and platelet activation. J Biol Chem 258:11243, 1983. platelet-type von Willebrand disease. Thromb Haemost 108:946–954, 2012.
263. Bienz D, Schnippering W, Clemetson KJ: Glycoprotein V is not the thrombin activation 293. Woods AI, Sanchez-Luceros A, Bermejo E, et al: Identification of p.W246L as a novel
receptor on human blood platelets. Blood 68:720–725, 1986. mutation in the GP1BA gene responsible for platelet-type von Willebrand disease.
264. Caen JP, Nurden AT, Jeanneau C, et al: Bernard-Soulier syndrome: A new platelet gly- Semin Thromb Hemost 40:151–160, 2014.
coprotein abnormality. Its relationship with platelet adhesion to subendothelium and 294. Pincus MR, Carty RP, Miller JL: Structural implications of the substitution of Val for
with the factor VIII von Willebrand protein. J Lab Clin Med 87:586–596, 1976. Met at residue 239 in the alpha chain of human platelet glycoprotein Ib. J Protein Chem
265. Andrews RK, Harris SJ, McNally T, Berndt MC: Binding of purified 14–3–3 zeta sig- 13:629–633, 1994.
naling protein to discrete amino acid sequences within the cytoplasmic domain of the 295. Dumas JJ, Kumar R, McDonagh T, et al: Crystal structure of the wild-type von Willebrand
platelet membrane glycoprotein Ib-IX-V complex. Biochemistry 37:638–647, 1998. factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex
266. Sullam PM, Hyun WC, Szollosi J, et al: Physical proximity and functional interplay of bearing von Willebrand disease mutations. J Biol Chem 279:23327–23334, 2004.
the glycoprotein Ib-IX-V complex and the Fc receptor FcgammaRIIA on the platelet 296. Suva LJ, Hartman E, Dilley JD, et al: Platelet dysfunction and a high bone mass phe-
plasma membrane. J Biol Chem 273:5331–5336, 1998. notype in a murine model of platelet-type von Willebrand disease. Am J Pathol 172:
267. Falati S, Edmead CE, Poole AW: Glycoprotein Ib-V-IX, a receptor for von Willebrand 430–439, 2008.
factor, couples physically and functionally to the Fc receptor g -chain, Fyn, and Lyn to 297. Doggett TA, Girdhar G, Lawshe A, et al: Alterations in the intrinsic properties of the
activate human platelets. Blood 94:1648–1656, 1999. GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand
268. Arthur JF, Gardiner EE, Matzaris M, et al: Glycoprotein VI is associated with GPIb-IX-V disease mutation, Gly233Val. Blood 102:152–160, 2003.
on the membrane of resting and activated platelets. Thromb Haemost 93:716–723, 2005. 298. Tait AS, Cranmer SL, Jackson SP, et al: Phenotype changes resulting in high-affinity
269. Feng S, Resendiz JC, Christodoulides N, et al: Pathological shear stress stimulates the binding of von Willebrand factor to recombinant glycoprotein Ib-IX: Analysis of the
tyrosine phosphorylation of alpha-actinin associated with the glycoprotein Ib-IX com- platelet-type von Willebrand disease mutations. Blood 98:1812–1818, 2001.
plex. Biochemistry 41:1100–1108, 2002. 299. Takahashi H, Nagayama R, Hattori A, Shibata A: Botrocetin- and polybrene-induced
270. Aziz KA: An acquired form of Bernard Soulier syndrome associated with acute myeloid platelet aggregation in platelet-type von Willebrand disease. Am J Hematol 18:179–189,
leukemia. Saudi Med J 26:1095–1098, 2005. 1985.
271. Kaur H, Ozelo M, Scovil S, et al: Systematic analysis of bleeding phenotype in PT-VWD 300. Miller JL, Kupinski JM, Castella A, Ruggeri ZM: Von Willebrand factor binds to plate-
compared to type 2B VWD using an electronic bleeding questionnaire. Clin Appl lets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
Thromb Hemost 20:765–771, 2014. J Clin Invest 72:1532–1542, 1983.
272. Takahashi H: Studies on the pathophysiology and treatment of von Willebrand’s 301. Scott JP, Montgomery RR: The rapid differentiation of type IIb von Willebrand’s dis-
disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von ease from platelet-type (pseudo-) von Willebrand’s disease by the “neutral” monoclonal
Willebrand’s disease. Thromb Res 19:857–867, 1980. antibody binding assay. Am J Clin Pathol 96:723–728, 1991.
273. Krizek DM, Rick ME, Williams SB, Gralnick HR: Cryoprecipitate transfusion in variant 302. Miller JL: Sorting out heightened interactions between platelets and von Willebrand
von Willebrand’s disease and thrombocytopenia. Ann Intern Med 98:484–486, 1983. factor. “IIB or not IIB?” is becoming an increasingly answerable question in the molec-
274. Weiss HJ, Meyer D, Rabinowitz R, et al: Pseudo-von Willebrand’s disease. An intrin- ular era. Am J Clin Pathol 96:681–683, 1991.
sic platelet defect with aggregation by unmodified human factor VIII/von Willebrand 303. Miller JL, Ruggeri ZM, Lyle VA: Unique interactions of asialo von Willebrand factor
factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med with platelets in platelet-type von Willebrand disease. Blood 70:1804–1809, 1987.
306:326–333, 1982. 304. Hamilton A, Ozelo M, Leggo J, et al: Frequency of platelet type versus type 2B von
275. Miller JL, Castella A: Platelet-type von Willebrand’s disease: Characterization of a new Willebrand disease. An international registry-based study. Thromb Haemost 105:
bleeding disorder. Blood 60:790–794, 1982. 501–508, 2011.
276. Gralnick HR, Williams SB, Shafer BC, Corash L: Factor VIII/von Willebrand factor 305. Takahashi H: Replacement therapy in platelet-type von Willebrand disease. Am J
binding to von Willebrand’s disease platelets. Blood 60:328–332, 1982. Hematol 18:351–362, 1985.
277. Takahashi H, Handa M, Watanabe K, et al: Further characterization of platelet-type von 306. Miller JL: Platelet-type von Willebrand’s disease. Clin Lab Med 4:319–331, 1984.
Willebrand’s disease in Japan. Blood 64:1254–1262, 1984. 307. Poon MC: Factor VIIa, in Platelets, 2nd ed, edited by AD Michelson, p 867. Academic
278. Nurden P, Lanza F, Bonnafous-Faurie C, Nurden A: A second report of platelet- Press, San Diego, 2007.
type von Willebrand disease with a Gly233Ser mutation in the GPIBA gene. Thromb 308. Fressinaud E, Signaud-Fiks M, Le Boterff C, Piot B: Use of recombinant factor VIIa
Haemost 97:319–321, 2007. (NovoSevenr) for dental extraction in a patient affected by platelet-type (pseudo-) von
279. Othman M, Notley C, Lavender FL, et al: Identification and functional characterization Willebrand disease. Haemophilia 4:299, 1998.
of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene 309. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing
resulting in platelet-type von Willebrand disease. Blood 105:4330–4336, 2005. no response to collagen fail to express surface glycoprotein Ia. Nature 318:470–472, 1985.
280. Enayat MS, Guilliatt AM, Lester W, et al: Distinguishing between type 2B and pseudo-von 310. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, et al: Deficiency of platelet membrane
Willebrand disease and its clinical importance. Br J Haematol 133:664–666, 2006. glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: A
281. Bryckaert MC, Pietu G, Ruan C, et al: Abnormality of glycoprotein Ib in two cases of defect in platelet spreading. Blood 68:692–695, 1986.
“pseudo”-von Willebrand’s disease. J Lab Clin Med 106:393–400, 1985. 311. Beer JH, Nieuwenhuis HK, Sixma JJ, Coller BS: Deficiency of antibody 6F1 binding to
282. Othman M, Kaur H, Emsley J: Platelet-type von Willebrand disease: New insights the platelets of a patient with an isolated defect in platelet-collagen interaction. Circulation
into the molecular pathophysiology of a unique platelet defect. Semin Thromb Hemost 78(Suppl):II-308, 1988.
39:663–673, 2013. 312. Coller BS, Beer JH, Scudder LE, Steinberg MH: Collagen-platelet interactions:
283. Othman M, Emsley J: Platelet-type von Willebrand disease: Toward an improved Evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect inter-
understanding of the “sticky situation.” Semin Thromb Hemost 40:146–150, 2014. action with platelet GPIIb/IIa mediated by adhesive proteins. Blood 74:182–192, 1989.
284. Miller JL, Cunningham D, Lyle VA, Finch CN: Mutation in the gene encoding the alpha 313. Kehrel B, Balleisen L, Kokott R, et al: Deficiency of intact thrombospondin and mem-
chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad brane glycoprotein Ia in platelets with defective collagen-induced aggregation and
Sci U S A 88:4761–4765, 1991. spontaneous loss of disorder. Blood 71:1074–1078, 1988.
285. Russell SD, Roth GJ: Pseudo-von Willebrand disease: A mutation in the platelet 314. Kunicki TJ, Williams SA, Nugent DJ: Genetic variants that affect platelet function. Curr
glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 81: Opin Hematol 19:371–379, 2012.
1787–1791, 1993. 315. Habart D, Cheli Y, Nugent DJ, et al: Conditional knockout of integrin alpha2beta1 in murine
286. Takahashi H, Murata M, Moriki T, et al: Substitution of Val for Met at residue 239 of megakaryocytes leads to reduced mean platelet volume. PLoS One 8:e55094, 2013.
platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand 316. McCall-Culbreath KD, Zutter MM: Collagen receptor integrins: Rising to the challenge.
disease. Blood 85:727–733, 1995. Curr Drug Targets 9:139–149, 2008.
287. Kunishima S, Heaton DC, Naoe T, et al: De novo mutation of the platelet glycoprotein 317. Yamamoto N, Ikeda H, Tandon NN, et al: A platelet membrane glycoprotein (GP) defi-
Ib alpha gene in a patient with pseudo-von Willebrand disease. Blood Coagul Fibrinolysis ciency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36). Blood
8:311–315, 1997. 76:1698–1703, 1990.

Kaushansky_chapter 120_p2039-2072.indd 2067 9/21/15 2:22 PM